li001

The updated results from the Phase III TOPAZ-1 trial, with a median follow-up of about 41 months, provide the longest data yet for durvalumab combined with gemcitabine and cisplatin in advanced biliary tract cancer. The study continues to show a strong and lasting survival benefit for patients receiving the immunotherapy combination compared to standard chemotherapy […]

Pembrolizumab (Keytruda) has been approved for use before and after surgery in adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS ≥1). The treatment plan includes pembrolizumab alone before surgery, followed by pembrolizumab with standard radiation therapy (with or without cisplatin) after surgery, and continued pembrolizumab afterward.

The phase 1 FORAGER-1 trial tested vepugratinib (LY3866288), a selective oral FGFR3 inhibitor, in metastatic urothelial carcinoma (mUC) patients with FGFR3 alterations (15–20% of cases). Unlike older pan-FGFR inhibitors, vepugratinib targets FGFR3 specifically to reduce off-target toxicity. As a single agent, 200 mg twice daily showed the best balance of efficacy and safety, producing a 34% overall

A new combination of darovasertib and crizotinib shows remarkable promise for metastatic uveal melanoma (MUM), a historically hard-to-treat eye cancer. In the Phase 1/2 OptimUM-01 trial, patients receiving this therapy lived a median of 21.1 months—nearly double the usual survival—and went about seven months without disease progression, more than twice the expected duration. The treatment achieved a